Interviews

Moshe Levy, MD discusses the ongoing phase 3b study of asciminib in patients with chronic myeloid leukemia in chronic phase.

Jorge E. Cortes, MD, discusses the current therapies available to treat patients with chronic myeloid leukemia and how to choose between them when there is similar efficacy.

Neeraj Agarwal, MD, discusses how the prostate-specific antigen responses correlate with survival outcomes in 2 phase 3 trials of apalutamide in patients with advanced prostate cancer.

Chung-Han Lee, MD, PhD, discusses the phase 2 KEYNOTE-B61 trial of pembrolizumab plus lenvatinib in patients with non–clear cell renal cell carcinoma.

Corey S. Cutler, MD, MPH, FRCPC, discusses the trial of belumosudil in patients with chronic graft-vs-host disease.

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.

Nelson J. Chao, MD, discusses a shift at Duke Cancer Institute from in-office care to home care in patients undergoing hematopoietic stem cell transplantation for hematologic malignancies.

Smruthy Sivakumar, PhD, discusses a large-scale analysis of comprehensive genomic profiling utilization and ancestral characterization of the genomic landscape in patients with advanced prostate cancer.

Amaia Lujambio Goizueta, PhD, discusses mutations commonly seen in hepatocellular carcinoma, and the targeted therapies available for these tumors.

Larry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.

Nizar M. Tannir, MD, FACP, discusses why telaglenastat in combination with cabozantinib did not improve efficacy in compared with cabozantinib alone in patients with metastatic renal cell carcinoma.

Christopher R. Flowers, MD, discusses the current therapies used for patients with relapsed/refractory diffuse large B-cell lymphoma and goes into specifics of the L-MIND trial after the long-term follow-up.

Thomas G. Martin, MD, discusses the use of anti-CD38 antibodies in patients with multiple myeloma.

Othman Al-Sawaf, MD, discusses the use of venetoclax plus obinutuzumab in patients with untreated chronic lymphocytic leukemia on the CLL14 study.

Dennis J. Slamon, MD, PhD, discusses the subgroup benefits and safety profile of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Bijal Shah, MD, MS, discusses the results of treatment with the chimeric antigen receptor T-cell therapy brexucabtagne autoleucel in the ZUMA-3 trial in patients with acute lymphoblastic leukemia.

Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.

Neeraj Agarwal, MD, discusses the health-related quality of life and patient-reported outcomes in the TITAN trial of apalutamide versus placebo patients with metastatic castration-sensitive prostate cancer.

Stephen J. Schuster, MD, discusses tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma in the phase 2 Elara trial and the 5-year follow-up of a smaller CAR T-cell trial.

Larry D. Anderson, Jr, MD, PhD, discusses the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.

In an interview with Targeted Oncology, David W. Dougherty, MD, discussed how the COVID-19 pandemic has changed the cancer care space.

Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.

Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.

Maurie Markman, MD, addresses different treatment options, including checkpoint inhibitors, for patients with endometrial cancer.

Mounzer Agha, MD, discusses the phase 2 CARTITUDE-2 trial looking at ciltacabtagene autoleucel in patients with multiple myeloma.

Jyoti Malhotra, MD, MPH, discusses the preliminary efficacy signals of the combination therapy plinabulin, nivolumab, and ipilimumab in patients with relapsed/refractory small cell lung cancer.

Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.

Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.